Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer

Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer
复制标题

DOI:
10.21873/anticanres.12603
复制
发表时间:
2018-06-01
影响因子:
2
通讯作者:
Shimada, Mitsuo
Shimada, Mitsuo
中科院分区:
医学4区
文献类型:
--
作者:
Enkhbat, Tumenjin;Nishi, Masaaki;Shimada, Mitsuo

文献摘要

被引文献

相似文献

背景/目的:程序性细胞死亡蛋白1(PD-1)-1-程序性细胞死亡配体1(PD-L1)轴通过抑制T细胞活化与免疫耐受有关,本研究旨在阐明PD-1和PD-11在结直肠癌中的表达意义,并分析PD-1、PD-11、转化生长因子-β(TGF-β)和Forkhead box P3(FOXP3)在结直肠癌中表达的关系。患者和方法:共有116名因II/III期结直肠癌接受根治性结肠切除术的患者纳入研究。免疫组织化学方法检测PD-1、PD-11、转化生长因子/β和Foxp3的表达,Kaplan-Meier法检测其与预后因素的关系。结果:PD-1的表达与PD-L1、TGF-f3和Foxp3的表达呈正相关,PD-1和PD-11阳性组的总体生存率明显降低。多因素分析显示PD-LL阳性是独立的危险因素,PD-LL阳性组无病生存(DFS)倾向于PD-LL阳性组,双阳性组预后明显差。结论:PD-1和PD-11的表达与结直肠癌患者的预后不良有关,并与转化生长因子-β和Foxp3的表达有关。
Background/Aim: Programmed cell death protein 1 (PD-1 )1 programmed cell death ligand 1(PD-L1) axis is associated with immune tolerance via inhibition of T cell activation.The aim of this study was to clarify the significance of PD-1 and PD-Ll expressions and analyze the relationships between PD-1, PD-Ll , transforming growth factor beta- (TGF-beta) and Forkhead box P3 (Foxp3) expressions in colorectal cancer (CRC). Patients and Methods: A total of 116 patients who underwent curative colectomy for stage II/III CRC were included in the study. PD-1, PD-Ll , TGF/beta, and Foxp3 expressions were examined by immunohistochemistry and related to prognostic factors by Kaplan-Meier. Results: PD-1 expression was correlated with PD-L1, TGF-f3, and Foxp3 expressions.Overall survival rates were significantly poorer in the PD-1 and PD-Ll-positive groups. Multivariate analysis showed that PD-Ll -positive is an independent risk factor.Disease free survival (DFS) was tended in the PD-Ll-positive group.The group with double-positive expression had significantly poorer prognosis. Conclusion:P D-1 and PD-Ll expressions were associated with a poor prognosis and correlated with TGF-beta and Foxp3 expressions in patients with CRC.